Pharma · Private company
Daiichi Sankyo
Track this companyFree. Adds Daiichi Sankyo to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs15From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline15
- BevacizumabPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- CisplatinPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Datopotamab DeruxtecanPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 3 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- Trastuzumab DeruxtecanPhase 3 · Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- DS-1103aPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- DS-3939aPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Patritumab Deruxtecan (Fixed dose)Phase 2 · Non-Small Cell Lung Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- Patritumab Deruxtecan (Up-Titration)Phase 2 · Non-Small Cell Lung Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- Valemetostat TosylatePhase 2 · Relapsed/Refractory Peripheral T-Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate CancerPHASE2 · NOT_YET_RECRUITING · started Nov 7, 2026ClinicalTrials.gov NCT07925268 · fetched Nov 12, 2026
- A Study of DS-3939a in Participants With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Oct 13, 2026ClinicalTrials.gov NCT07739966 · fetched Nov 12, 2026
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)PHASE3 · RECRUITING · started Oct 7, 2026ClinicalTrials.gov NCT07743164 · fetched Nov 12, 2026
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)PHASE3 · RECRUITING · started Sep 18, 2026ClinicalTrials.gov NCT07776691 · fetched Nov 12, 2026
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)PHASE1_PHASE2 · RECRUITING · started Jul 6, 2026ClinicalTrials.gov NCT07630974 · fetched Nov 12, 2026
- An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.PHASE4 · RECRUITING · started Jun 24, 2026ClinicalTrials.gov NCT07357597 · fetched Nov 12, 2026
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)PHASE1_PHASE2 · RECRUITING · started Mar 27, 2026ClinicalTrials.gov NCT07405151 · fetched Nov 12, 2026
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)PHASE1_PHASE2 · RECRUITING · started Jan 29, 2026ClinicalTrials.gov NCT07227597 · fetched Nov 12, 2026
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic AlterationsPHASE3 · RECRUITING · started Oct 31, 2025ClinicalTrials.gov NCT07291037 · fetched Nov 12, 2026
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)PHASE3 · RECRUITING · started Jul 21, 2025ClinicalTrials.gov NCT07060807 · fetched Nov 12, 2026
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)PHASE3 · RECRUITING · started May 13, 2025ClinicalTrials.gov NCT06925737 · fetched Nov 12, 2026
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)PHASE2 · ACTIVE_NOT_RECRUITING · started May 13, 2025ClinicalTrials.gov NCT06780085 · fetched Nov 12, 2026
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).PHASE1_PHASE2 · RECRUITING · started Apr 15, 2025ClinicalTrials.gov NCT06843447 · fetched Nov 12, 2026
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)PHASE2 · RECRUITING · started Mar 20, 2025ClinicalTrials.gov NCT06797635 · fetched Nov 12, 2026
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)PHASE3 · RECRUITING · started Mar 19, 2025ClinicalTrials.gov NCT06819007 · fetched Nov 12, 2026
- A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerPHASE1 · RECRUITING · started Jan 29, 2025ClinicalTrials.gov NCT06807632 · fetched Nov 12, 2026
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsPHASE3 · RECRUITING · started Apr 11, 2024ClinicalTrials.gov NCT06357533 · fetched Nov 12, 2026
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 19, 2023ClinicalTrials.gov NCT05683171 · fetched Nov 12, 2026
- Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)PHASE3 · ACTIVE_NOT_RECRUITING · started Jan 11, 2023ClinicalTrials.gov NCT05555732 · fetched Nov 12, 2026
- Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 3, 2021ClinicalTrials.gov NCT04703192 · fetched Nov 12, 2026
- HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Feb 2, 2021ClinicalTrials.gov NCT04619004 · fetched Nov 12, 2026
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 18, 2020ClinicalTrials.gov NCT04482309 · fetched Nov 12, 2026
- KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)PHASE1_PHASE2 · RECRUITING · started Dec 19, 2019ClinicalTrials.gov NCT04165070 · fetched Nov 12, 2026
- KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)RECRUITING · started Dec 19, 2019ClinicalTrials.gov NCT04165798 · fetched Nov 12, 2026
- Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromePHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 31, 2018ClinicalTrials.gov NCT03661307 · fetched Nov 12, 2026